Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 216.11M | 212.07M | 203.47M | 201.35M | 198.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 216.11M | 212.07M | 203.47M | 201.35M | 198.77M |
| Cost of Revenue | 13.04M | 11.80M | 11.40M | 11.40M | 11.31M |
| Gross Profit | 203.06M | 200.27M | 192.07M | 189.96M | 187.46M |
| SG&A Expenses | 237.95M | 214.26M | 191.56M | 166.41M | 146.41M |
| Depreciation & Amortization | 7.01M | 7.01M | 7.01M | 7.01M | 7.27M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 367.27M | 333.17M | 304.28M | 273.80M | 239.43M |
| Operating Income | -151.17M | -121.09M | -100.81M | -72.45M | -40.66M |
| Income Before Tax | -138.65M | -107.14M | -85.00M | -55.63M | -22.92M |
| Income Tax Expenses | 81.83M | -22.94M | -18.06M | -11.38M | -4.02M |
| Earnings from Continuing Operations | -220.47 | -84.20 | -66.94 | -44.25 | -18.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.47M | -84.20M | -66.94M | -44.25M | -18.90M |
| EBIT | -151.17M | -121.09M | -100.81M | -72.45M | -40.66M |
| EBITDA | -143.06M | -113.07M | -92.87M | -64.56M | -32.53M |
| EPS Basic | -3.74 | -1.43 | -1.14 | -0.76 | -0.33 |
| Normalized Basic EPS | -1.49 | -1.21 | -0.98 | -0.67 | -0.32 |
| EPS Diluted | -3.74 | -1.44 | -1.15 | -0.77 | -0.33 |
| Normalized Diluted EPS | -1.49 | -1.21 | -0.98 | -0.67 | -0.32 |
| Average Basic Shares Outstanding | 235.71M | 234.92M | 234.09M | 233.32M | 232.55M |
| Average Diluted Shares Outstanding | 235.71M | 234.92M | 234.09M | 233.32M | 232.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |